Carnosine Supplementation Has No Effect on Inflammatory Markers in Adults with Prediabetes and Type 2 Diabetes: A Randomised Controlled Trial

What Was Tested

Researchers studied Carnosine in this randomized controlled trial publication.

However, human clinical trials examining the effects of carnosine on inflammatory biomarkers are scant.

The researchers conducted a secondary analysis of a double-blind randomised controlled trial (RCT) to examine the effects of carnosine supplementation on inflammatory markers and adipokines in participants with prediabetes or well-controlled type 2 diabetes (T2D).

Who Took Part

The study group was 88 participants.

The age groups tagged for this paper are adults, middle-aged adults and older adults, both men and women.

How the Study Was Run

In design terms this was a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Carnosine group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Carnosine.

Some participants received a placebo instead of Carnosine, giving a reference point.

A time span of 14 weeks appears in the methods.

The researchers measured serum concentrations of monocyte chemoattractant protein-1 (MCP-1), interleukin (IL)-6, IL-10, C-reactive protein (CRP), tumour necrosis factor-α (TNF-α), adiponectin, leptin, adipsin, serpin, and resistin levels at baseline and after 14 weeks.

The trial was registered at clinicaltrials.gov (NCT02917928).

What Was Measured

The subject headings attached to it are Carnosine, Diabetes Mellitus, Type 2, Prediabetic State, Dietary Supplements, Biomarkers, Inflammation and Adipokines.

Author keywords: cytokine, insulin resistance, prediabetes, randomised trial and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Carnosine in 88 participants over 14 weeks.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Nutrients), a journal based in Switzerland.

More context: the Carnosine compound page, all human trials.